Clinical trials: Intrauterine Systems
Healthy
Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion
The study is a randomized controlled trial comparing outcomes of immediate postplacental insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) vs.
- Trial name
- NCT00635362
- Testing
- Levonorgestrel-releasing intrauterine system (LNG-IUS)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Contraception
Early vs. Interval Postpartum IUD Insertion
Intrauterine devices (IUDs) are historically placed at a six-week postpartum visit for women who desire intrauterine contraception after delivery.
- Trial name
- EPPIUD (NCT03462758)
- Testing
- IUD
- Where
- 4 sites in United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Epilepsy, Contraception
Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
The investigators will conduct a prospective, seven-month pilot study to explore pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the levonorgestrel intrauterine system (LNG IUS) for…
- Trial name
- WESAIL (NCT02362373)
- Testing
- levonorgestrel IUS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Contraception
Immediate Postplacental IUD Insertion
The study will be a randomized clinical trial. Women with less than 10 prenatal visits and/or 2 or more no show visits who desire an Intrauterine Device (IUD) will be considered for enrollment.
- Trial name
- NCT02169869
- Testing
- Mirena, Paragard
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Oregon Health and Science University
Undesired Intrauterine Pregnancy, First Trimester Pregnancy
Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions
In the United States, the majority of first-trimester surgical abortions are performed in outpatient clinics that utilize a wide variety of oral and intravenous regimens for pain control.
- Trial name
- NCT01011634
- Testing
- Intravenous moderate sedation versus oral medication
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Menorrhagia
Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.
- Trial name
- NCT00360490
- Testing
- Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 165 people
- Sponsor
- Bayer
Contraception
Evaluation of the Efficacy and Safety of LevoCept
To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study
- Trial name
- NCT02882191
- Testing
- LevoCept
- Where
- 16 sites in United States
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Sebela Women's Health Inc.
Contraception
Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)
The purpose of this study is to investigate if drug doses lower than the one released from Mirena® would be as effective for contraception as Mirena®.
- Trial name
- NCT00185380
- Testing
- Levonorgestrel IUS (BAY86-5028, G04209B), Levonorgestrel IUS (BAY86-5028, G04209C), Levonorgestrel IUS (Mirena, BAY86-5028)
- Where
- 35 sites in Finland, Hungary and 3 more
- Volunteers
- 742 people
- Sponsor
- Bayer
Menorrhagia, Metrorrhagia
Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device (IUD).
- Conditions
- Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
- Trial name
- NCT02824224
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Postpartum Contraception
Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding
This will be a randomized clinical trial of 190 women aged 18-45 who plan to breastfeed their infant for at least 6 months and desire to use the LNG-IUS as their primary contraceptive method postpartum.
- Trial name
- PPIUD1 (NCT01555931)
- Testing
- Levonorgestrel-releasing intrauterine system
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of North Carolina, Chapel Hill
Contraception, Malposition of Intrauterine Contraceptive Device
LNG-IUS at 2 Weeks Postpartum
This is a study of 50 postpartum women interested in having the Mirena® LNG-IUS placed for contraception. The Mirena® is an FDA approved intrauterine contraceptive device that provides contraception for 5 years with excellent…
- Trial name
- LNG-IUS (NCT02121067)
- Testing
- Levonorgestrel Intrauterine System (LNG-IUS)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Postpartum Period
Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial
In order to determine the timing of LNG-IUS insertion that results in a greater proportion of women using the LNG-IUS at 6-months post-partum, we will perform a randomized control trial of interval versus immediate post-placenta…
- Trial name
- MISTIC (NCT01272960)
- Testing
- Post-Placenta Mirena Insertion, Interval Insertion
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Pregnancy, Fetal Macrosomia
Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight
The aim of this prospective longitudinal study was to investigate the relationship between placental thickness during the second and third trimesters and placental and birth weights.
- Conditions
- Pregnancy, Fetal Macrosomia, Intrauterine Growth Restriction
- Trial name
- NCT02473991
- Testing
- ultrasound
- Where
- Egypt
- Volunteers
- 395 people, healthy volunteers welcome
- Sponsor
- Ain Shams Maternity Hospital
HIV
Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women
This study will inform international medical guidelines as to whether the Levonorgestrel intrauterine device (LNG IUD), a highly effective long-acting reversible contraceptive method, is safe and acceptable as compared to the…
- Trial name
- NCT01721798
- Testing
- Mirena levonorgestrel IUD, Copper T-380a IUD
- Where
- South Africa
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- FHI 360
Polycystic Ovary Syndrome
Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands
Polycystic ovary syndrome (PCOS) is among the most common endocrine disorders in premenopausal women, affecting 7-10% of this population.
- Trial name
- NCT00364949
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Postpartum Period
Bleeding Patterns and Complications After Postpartum IUD Placement: a Pilot Study
The purpose of the study is to determine the feasibility of placing the levonorgestrel-releasing intrauterine system (LNG - IUS, Mirena®) post-delivery.
- Trial name
- NCT01309919
- Testing
- IUD, Diary
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Baystate Medical Center
Pain Control With IUD Insertion
Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement
Intrauterine device (IUD) placement can be painful for patients during and after the procedure. Fear of pain from IUD insertion can be a barrier to obtaining this highly effective long acting reversible contraception.
- Trial name
- NCT01664559
- Testing
- Ketorolac, Normal Saline
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Lynn Ngo
Menopause
Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).
The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age.
- Trial name
- NCT00185458
- Testing
- LNG IUS
- Where
- 12 sites in Belgium, Finland and 2 more
- Volunteers
- 394 people
- Sponsor
- Bayer
Pregnancy, Infertility
Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis
The primary research hypothesis is that microsurgical varicocelectomy will result in an increase in live birth in infertile couples where the male partner has a palpable varicocele and an abnormal semen analysis in comparison to…
- Trial name
- VIA (NCT00767338)
- Testing
- Timed intercourse, Microsurgical varicocelectomy, Intrauterine insemination
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Contraception
Naproxen for Pain Control With Intrauterine Device Insertion
The purpose of this study is: 1. To evaluate whether 550 mg of naproxen sodium reduces pain scores with IUD insertion on a 0-10cm visual analogue scale compared to placebo (primary outcome). 2.
- Trial name
- NCT02388191
- Testing
- Naproxen sodium
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Planned Parenthood League of Massachusetts